FLT3 and acute myeloid leukemia: The eligibility cutoffs in the RATIFY and QuANTUM-First studies were a FLT3 allelic ratio ≥0.03 and a FLT3 variant allelic frequency ≥0.05, respectively, and thus randomized data supporting the use of FLT3 inhibitors in the context of very low-burden FLT3-mutated AML are lacking.